FLORIDA UPDATE
OVERVIEW OF FLORIDA OBJECTIVES

Florida drug-Related Outcomes and Surveillance Tracking System (FROST)
- http://frost.med.ufl.edu
- PDMP mandatory use/enrollment status maps
- Opioid pain reliever and heroin deaths, national perspective

Special populations
- “Holy Trinity” (opioid-benzodiazepine-carisoprodol) prescribing characteristics

Relevant Publications
Interactive roll-overs for state-specific information

Research is current as of Jan 17, 2017. Missouri does not have PDMP legislation. Source:
http://www.pdmnpasst.org/content/pdmp-maps-and-tables
http://www.narcod.org/prescription-monitoring-programs-clip
MANDATORY PDMP ENROLLMENT

PDMP Mandatory Enrollment and Query

Research is current as of Jan 17, 2017, Missouri does not have PDMP legislation.
Source:
http://www.pdmpassist.org/content/pdmp-maps-and-tables
http://www.rsumd.org/prescription-monitoring-programs.cfm
Interactive expansion to time-series view
DRUG OVERDOSES INVOLVING OPIOIDS

Note: Click the state tile to see the state-specific trend. To cancel, click a blank area on the file grid map.

*Calculate Rates Per: 100,000 population
Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2015 on CDC WONDER Online Database, released December, 2016.
### “HOLY TRINITY” CHARACTERISTICS (2013-2015)

<table>
<thead>
<tr>
<th>Measure</th>
<th>O/B/C</th>
<th>O/B-only</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Individual-prescriber-pharmacy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Individuals with Rx</td>
<td>65,325</td>
<td>1,049,897</td>
</tr>
<tr>
<td>Prescribers</td>
<td>19,643</td>
<td>69,884</td>
</tr>
<tr>
<td>Prescribers - opioids</td>
<td>13,677</td>
<td>56,333</td>
</tr>
<tr>
<td>Prescribers - benzodiazepines</td>
<td>13,994</td>
<td>54,067</td>
</tr>
<tr>
<td>Prescribers - carisoprodol</td>
<td>12,082</td>
<td>N/A</td>
</tr>
<tr>
<td>Pharmacies</td>
<td>4,916</td>
<td>5,800</td>
</tr>
<tr>
<td><strong>Episodes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rx episodes</td>
<td>1,613,429</td>
<td>11,287,381</td>
</tr>
<tr>
<td>Rx episodes with O/B-only from same prescriber</td>
<td>982,564 (61%)</td>
<td>6,355,367 (56%)</td>
</tr>
<tr>
<td>Rx episodes with O/B/C same prescriber</td>
<td>916,272 (57%)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Distinct counts O/B/C = Opioids/Benzodiazepines/Carisoprodol

Full study will be presented at the National Rx Drug Abuse & Heroin Summit, April 17-20, 2017
MORPHINE MILLIGRAM EQUIVALENT (MME)

- Prevalence of high-risk MMEs ~2x higher for O/B/C (●)
- Mean daily MME of O/B/C much higher than CDC Rx guideline

% Individuals receiving >100 MMEs daily within episode

- Mean daily MME

- [VALUE]
RELEVANT PUBLICATIONS


THANK YOU